µÏÍþ¹ú¼Ê


µÏÍþÖÆµÏÍþ¹ú¼Ê µÏÍþÖÆµÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
2022 WCLC | µÏÍþÖÆµÏÍþ¹ú¼Ê°¢ÃÀÌæÄá21ƪժҪÉÁÒ«µÇ¶¥ Ô­ÑÐÖ®¹âÕ¹ÏÖÖйú´´ÐÂÁ¦Á¿
·¢²¼ÈÕÆÚ£º2022/08/04
×ÖºÅ

2022Äê¹ú¼Ê·Î°©Ñо¿Ð­»á(IASLC)ÊÀ½ç·Î°©´ó»á(WCLC)¼´½«ÓÚ2022Äê8ÔÂ6ÈÕÖÁ9ÈÕÔڰµØÀûάҲÄɾÙÐС£±¾´ÎÊÀ½ç·Î°©´ó»á½«·¢±íÓÉÖйú´ó½ר¼Ò×÷ΪµÚÒ»×÷Õß»òͨѶ×÷ÕßµÄEGFR-TKIÏà¹Ø³É¹û¹²31ƪ£¬ÆäÖаüÀ¨µÏÍþÖÆµÏÍþ¹ú¼Ê×ÔÖ÷´´ÐµÏÍþ¹ú¼Ê¼×»ÇËá°¢ÃÀÌæÄáÆ¬(ÉÌÆ·Ãû£º°¢ÃÀÀÖ?)Ïà¹Ø³É¹û21ƪ£¬Õ¼×ÜÆªÊýµÄ68%£¬ÔÚËùÓÐEGFR-TKIÖÐÃûÁеÚÒ»¡£


WCLCÊÇÊÀ½çÉϹæÄ£×î´óµÄÖÂÁ¦Óڷΰ©ºÍÆäËüÐØ²¿¶ñÐÔÖ×ÁöµÄ¶àѧ¿ÆÖ×Áöѧ»áÒ飬ÿ½ì¶¼»áÓжàÏîÖØ°õÁÙ´²Ñо¿½á¹û¹«²¼²¢Óɴ˸üÐÂÁÙ´²Êµ¼ù¡£2022ÄêWCLC½«ÔÙ´ÎΪÀ´×ÔÈ«Çò100¶à¸ö¹ú¼ÒµÄÊýǧÃûרҵÈËÊ¿ÌṩÏßϽ»Á÷ƽ̨£¬¹²Í¬Ì½Ìַΰ©ºÍÆäËüÐØ²¿¶ñÐÔÖ×ÁöµÄ×îÇ°ÑØÖÎÁƽøÕ¹¡£


°¢ÃÀÌæÄáÊǵÏÍþÖÆµÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄÊ׸öÖйúÔ­´´Èý´úEGFR-TKI£¬Ò²ÊÇÈ«ÇòÊ׸öÖÐλÎÞ½øÕ¹Éú´æÆÚ(mPFS)³¬¹ý1Äê(¶þÏßʹÓÃ)µÄÈý´úEGFR-TKI£¬Æ¾½è׿ԽµÄÁÆÐ§ºÍ°²È«ÐÔÓÅÊÆ£¬ÒѶà´ÎµÃµ½¹ú¼ÊȨÍþÈϿɡ£2022Äê5Ô£¬°¢ÃÀÌæÄáAENEASÑо¿½á¹ûÔÚ¹ú¼ÊÖøÃûÖ×ÁöѧÆÚ¿¯¡¶ÁÙ´²Ö×ÁöѧÔÓÖ¾¡·(Journal of Clinical Oncology£¬JCO£¬IF:44.544)·¢±í£¬×îÐÂÄÔ×ªÒÆÑÇ×éÊý¾ÝÁÁÏàÃÀ¹úÁÙ´²Ö×Áöѧ»á(ASCO)Äê»á£¬ÔٴξªÑÞ¹ú¼ÊÖ×Áöѧ½ç¡£


Ϊ½øÒ»²½Ì½Ë÷°¢ÃÀÌæÄáÔڷΰ©Ï¸·ÖÁìÓòµÄÖÎÁÆÇ±Á¦£¬»Ý¼°È«Çò¸ü¶àNSCLC»¼Õߣ¬»ùÓÚ°¢ÃÀÌæÄáĿǰ³É¹¦µÄÑз¢¾­Ñ飬ÆäÁÙ´²¼ÛÖµ»¹ÔÚ½øÒ»²½ÍÚ¾òÖУ¬°üÀ¨°¢ÃÀÀÖ?ÁªºÏº¬²¬Ë«µÏÍþ¹ú¼Ê»¯ÁÆÒ»ÏßÖÎÁÆÓÐÃô¸ÐÍ»±äNSCLC¡¢¸¨ÖúÖÎÁÆNSCLCµÈÊÊÓ¦Ö¢µÄ¶à¸öÁÙ´²Ñо¿£¬½«Îª¸ü¶àNSCLC»¼ÕßÌṩ´ÓÔçÆÚµ½ÍíÆÚ£¬´ÓΧÊÖÊõÆÚ¸¨ÖúÖÎÁÆ¡¢¶þÏß¼°ºóÏßÖÎÁƵ½Ò»ÏßÖÎÁƵÈÈ«·½Î»¶àά¶ÈµÄÓõÏÍþ¹ú¼Ê·½°¸¡£


±¾½ìWCLCÉÏ£¬°¢ÃÀÌæÄá¶à´ï21ƪժҪÈëÑ¡£¬°üÀ¨7ƪ³£¹æÕªÒª(Ñо¿Êý¾Ý)¡¢3ƪ²¡Àý±¨µÀÒÔ¼°11ƪÕýÔÚ½øÐÐÖеÄÁÙ´²Ñо¿£¬½«´øÀ´°¢ÃÀÌæÄáÔÚ·ÇСϸ°û·Î°©(NSCLC)°ÐÏòÁªºÏÖÎÁÆ¡¢ÄÔ(Ĥ)×ªÒÆÖÎÁƵȷ½Ïò×îÐÂÑо¿½øÕ¹¡£


³£¹æÕªÒª

ÕªÒª±àºÅ£ºEP08.02-003

Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation and ctDNA Cleared Analysis

°¢ÃÀÌæÄáÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚ·Î°©

×÷ÕߣºÀîÑàΡ  Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº

¼ò½é£º±¾Ñо¿£¨NCT04646824£©ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬Ö¼Ôڹ۲찢ÃÀÌæÄáÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆ¢ó-¢ôÆÚEGFRÍ»±äNSCLC»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔ¡£ÖÎÁÆ·½°¸Îª°¢ÃÀÌæÄá110mg/dÁªºÏÅàÃÀÇúÈüºÍ¿¨²¬4ÖÜÆÚ£¬ºó°¢ÃÀÌæÄáÁªºÏÅàÃÀÇúÈüά³ÖÖÎÁÆ£¬Ö±ÖÁ³öÏÖ²»¿ÉÄÍÊܵ;ÐÔºÍÖ×Áö½øÕ¹¡£½ØÖ¹µ½2021Äê11Ô£¬¹²ÕÐļÁË34Àý»¼Õߣ¬×ÜÈËȺORR88.2%£¬ÆäÖÐ19Àý»ùÏßÄÔ×ªÒÆ»¼ÕßORR89.4%£¬ºÏ²¢TP53ÑÇ×éORR 92.3%£¨12/13£©£¬78.6%£¨22/28£©µÄ»¼Õß½ÓÊÜÖÎÁÆ2-4¸öÖÜÆÚºó³öÏÖÁËctDNAÇåÁ㣬¶¯Ì¬ÇåÁãÓë·ñÓëORRÁÆÐ§¸ß¶ÈÏà¹Ø£¨ORR90.9%vs 33.3%£©£¬ÇÒ°²È«ÐԿɿأ¬×î³£¼ûµÄ²»Á¼Ê¼þAEÊÇÖÐÐÔÁ£Ï¸°û¼õÉÙ¡¢·¦Á¦ºÍÑáʳµÈ£¬AE¶àÓ뻯ÁÆÏà¹Ø£¬Î´·¢ÉúÖ°¢ÃÀÌæÄáÖжÏÖÎÁƵÄAE¡£


ÕªÒª±àºÅ£ºEP08.02-004

Aumolertinib in Treatment-Na?ve EGFR-mutant NSCLC Patients with Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆ£¨ARTISTRYÑо¿¶ÓÁÐ1£©

×÷ÕߣºÍõ»Û¾ê  ºÓÄÏÊ¡Ö×ÁöÒ½Ôº

¼ò½é£ºARTISTRYÑо¿£¨NCT04778800£©Ö¼Ôڹ۲첻ͬ¼ÁÁ¿°¢ÃÀÌæÄá¶Ô EGFRÍ»±äNSCLCÄÔ/ÄÔÄ¤×ªÒÆ»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔ£¬Æä¶ÓÁÐ1ÖÐÄÔʵÖÊ×ªÒÆ»¼Õß½ÓÊܰ¢ÃÀÌæÄá110mg/dÒ»ÏßÖÎÁÆ£¬µ±»¼Õß½ö­ÄÚ½øÕ¹¶øÆäÓಿλδ½øÕ¹Ê±£¬°¢ÃÀÌæÄá¼ÁÁ¿µÝÔöÖÁ165mg¡£½ØÖ¹2022Äê3Ô£¬¹²Èë×é14Àý»¼Õߣ¬ÆäÖÐ12Àý»¼ÕßÄÉÈëcFAS·ÖÎö¼¯£¨¡Ý1¸öCNS¿É²âÁ¿²¡ÔîºÍ/»ò²»¿É²âÁ¿²¡Ô£¬10Àý»¼ÕßÄÉÈëcEFR·ÖÎö¼¯£¨¡Ý1¸öCNS¿É²âÁ¿²¡Ô¡£iORRÔÚcFASºÍcEFRÖзֱðΪ66.7%ºÍ80%£¬iDCRÔÚÁ½¸ö·ÖÎö¼¯ÖоùΪ100%¡£3Àý½ÓÊÜ165mg°¢ÃÀÌæÄáÖÎÁƵϼÕßÖУ¬iDCR´ï100%¡£ÕûÌ尲ȫÐÔÁ¼ºÃ£¬Î´¼û3¼¶ÒÔÉϲ»Á¼Ê¼þ¡£


ÕªÒª±àºÅ£ºEP08.02-038

Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

°¢ÃÀÌæÄáÁªºÏ±´·¥Öéµ¥¿¹ºÍ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆ

¼ò½é£ºSpringlung150B(ChiCTR2000035591)ÊÇÒ»Ïîǰհ¡¢¶àÖÐÐÄÁÙ´²Ñо¿£¬ÄÉÈëδ¾­ÖÎÁƵÄÍíÆÚEGFRÍ»±äÄÔ×ªÒÆ·ÎÏÙ°©»¼Õߣ¬½ÓÊܰ¢ÃÀÌæÄá(110mg/d)ÁªºÏ±´·¥Öéµ¥¿¹£¨7.5mg/kg£©¡¢ÅàÃÀÇúÈû£¨500mg/©O£©4-6¸öÖÜÆÚÖÎÁƺó£¬Ëæ»ú·ÖΪ°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼Ê×飬°¢ÃÀÌæÄáÁªºÏ±´·¥µ¥¿¹×é»ò°¢ÃÀÌæÄáÁªºÏÅàÃÀÇúÈû×é¡£½ØÖ¹µ½2021Äê11Ô£¬¶Ô10Àý»¼Õß½øÐÐ4-6ÖÜÆÚÁªºÏÖÎÁƵÄÁÆÐ§ÆÀ¹À¡£10Àý»¼Õß¾ù´ïµ½PR£¬×ÜÌåORRΪ80%, DCRΪ100%£»Â­ÄÚiORRΪ90%£¬iDCRΪ 100%¡£»¼Õß°²È«ÐÔÁ¼ºÃ£¬×î³£¼û²»Á¼·´Ó¦ÎªÆ¤Õ40%£©£¬ÎÞ3¼¶ÒÔÉϲ»Á¼·´Ó¦¡£


ÕªÒª±àºÅ£ºEP08.02-050

A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

°¢ÃÀÌæÄáÁªºÏ±´·¥Öéµ¥¿¹ÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆµÄ»Ø¹ËÐÔÑо¿

×÷Õߣº·½Éê´æ  ÄϾ©ÊÐÐØ¿ÆÒ½Ôº

¼ò½é£ºÒ»Ïî°¢ÃÀÌæÄáÁªºÏ±´·¥Öéµ¥¿¹ÖÎÁÆEGFRÍ»±ä°éÓÐÄÔÄ¤×ªÒÆµÄNSCLCµÄ»Ø¹ËÐÔÑо¿£¬¹²ÄÉÈëÄϾ©ÐØ¿ÆÒ½Ôº5Àý½ÓÊܰ¢ÃÀÌæÄá(110 mg/Ìì)ÁªºÏ±´·¥Öéµ¥¿¹(7.5 mg/kg, 21ÌìÖÜÆÚ)ÖÎÁƵÄEGFRÍ»±ä°éÓÐÄÔÄ¤×ªÒÆµÄNSCLC»¼Õߣ¬ÖÐλÖÎÁÆÊ±¼ä11¸öÔ£¬ÖÎÁÆÇ°ÖÐλPSÆÀ·ÖΪ4·Ö£¬ÖÎÁƺóÖÐλPSÆÀ·ÖΪ1·Ö¡£ORR´ï80%£¬DCR´ï100%£¬Â­ÄÚORR´ï100%¡£ÁªºÏÖÎÁÆ2¸öÔºó£¬5Àý»¼Õß¾ùÐЭÄԴʲÕñ³ÉÏñ(MRI)¼ì²é£¬LMÃ÷ÏÔ¼õÉÙ£¬Ëæ×ÅÖÎÁƵļÌÐø£¬LM³ÖÐø»º½â£¬5Àý»¼Õß¾ùÎÞÈ«Éí»òLM²¡±ä½øÕ¹£¬°²È«ÐÔÁ¼ºÃ¡£


ÕªÒª±àºÅ£ºEP08.02-069

A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases

°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼Ê»òÁªºÏÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆµÄ»Ø¹ËÐÔÑо¿

×÷ÕߣºÀîÐÑÑÇ  Ö£ÖÝ´óѧµÚÒ»¸½ÊôÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïî°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼Ê»òÁªºÏÆäËüµÏÍþ¹ú¼ÊÎïÖÎÁÆEGFRÍ»±äÇÒ°éÓÐÄÔÄ¤×ªÒÆNSCLCµÄ»Ø¹ËÐÔÑо¿¡£¹²ÄÉÈëÖ£ÖÝ´óѧµÚÒ»¸½ÊôÒ½Ôº11Àý»¼Õߣ¬½ÓÊܰ¢ÃÀÌæÄá(110mg/Ìì)»òÁªºÏ»¯ÁÆ£¨»¯ÁÆ»ò±´·¥µ¥¿¹£©Ö±ÖÁ¼²²¡½øÕ¹»ñ²»ÄÍÊÜ¡£½á¹ûÏÔʾ£º²¿·Ö»º½â(PR)6Àý(54.5%)£¬²¡ÇéÎȶ¨(SD)3Àý(27.3%)£¬ORRΪ54.5%(6/11)£¬DCRΪ81.8%(9/11)¡£ËùÓл¼ÕßµÄÖÐλPFSΪ8.1¸öÔ¡£ÑÇ×é·ÖÎö£¬19delºÍL858R»¼ÕßÖÐλPFS·Ö±ðΪ11ºÍ7.6¸öÔ£¬EGFRÍ»±äÑôÐԺϲ¢TP53µÄÖÐλPFSΪ7.3¸öÔ£¬ÎÞTP53ºÏ²¢Í»±äµÄÖÐλPFSΪ11¸öÔ¡£


ÕªÒª±àºÅ£ºEP08.02-154

Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial

°¢ÃÀÌæÄáÁªºÏ°²ÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC

×÷Õߣº³Â»ªÁÖ  ¹ã¶«Ò½¿Æ´óѧ¸½ÊôÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬ÄÉÈëδ¾­ÖÎÁƵÄÍíÆÚ EGFRÍ»±äNSCLC»¼Õß¡£½ÓÊܰ¢ÃÀÌæÄá110mg/dÁªºÏ°²ÂÞÌæÄá12mg/dÖÎÁÆ£¬Ö±ÖÁ³öÏÖ²»¿ÉÄÍÊܵ;ÐÔºÍÖ×Áö½øÕ¹¡£½ØÖ¹µ½2022Äê3Ô£¬¹²ÕÐļÁË11Àý»¼Õߣ¬ÆäÖÐÄÔ×ªÒÆ7Àý£¨63.6%£©¡£11Àý»¼Õß¾ù´ïµ½PR£¬×ÜÌåORRΪ100%(11/11)£»7ÀýÄÔ×ªÒÆ»¼Õß½ÓÊÜ­Äڰв¡ÔîÆÀ¹À£¬ÆäÖÐ5Àý´ïµ½PR£¬2ÃûSD£¬iORRΪ71.4%(5/7)£¬iDCRΪ100%(7/7)¡£Ã»Óл¼ÕßÒò²»Á¼·´Ó¦Í£µÏÍþ¹ú¼Ê£¬°²È«ÐÔÁ¼ºÃ¡£


ÕªÒª±àºÅ£ºEP08.02-169

Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

°¢ÃÀÌæÄáÁªºÏ±´·¥Öéµ¥¿¹Ò»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC

×÷ÕߣºÖÓµîʤ  Ìì½òÒ½¿Æ´óѧ×ÜÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬ÄÉÈëδ¾­ÖÎÁƵĢôÆÚ EGFRÍ»±äNSCLC»¼Õß¡£ÖÎÁÆ·½°¸Îª°¢ÃÀÌæÄá110mg/dÁªºÏ±´·¥Öéµ¥¿¹7.5 mg/kg Q3W£¬Ö±ÖÁ³öÏÖ²»¿ÉÄÍÊܵ;ÐÔºÍÖ×Áö½øÕ¹¡£½ØÖ¹µ½2022Äê4Ô£¬¹²ÕÐļÁË19Àý»¼Õߣ¬ÆäÖÐ15Àý¿ÉÆÀ¹ÀÁÆÐ§£¬×ÜÈËȺORR 66.7%£¬DCR 93.3%¡£ÆäÖÐ12Àý»ùÏßÄÔ×ªÒÆ»¼ÕßORR 83.3%£¬8ÀýÄÔ×ªÒÆ»¼Õß½ÓÊÜ­Äڰв¡ÔîÆÀ¹À£¬iORRΪ87.5%£¬iDCRΪ100%¡£3Àý»¼Õß³öÏÖ3¼¶AE£¬1Àý»¼ÕßÒòÐØÍ´Í£Óñ´·¥Öéµ¥¿¹¡£


²¡Àý±¨µÀ

ÕªÒª±àºÅ£ºEP08.02-002

Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia

°ÂÏ£ÌæÄáÓÕ·¢¼äÖÊÐÔ·ÎÑ׺óת°¢ÃÀÌæÄáÖÎÁÆ

×÷ÕߣºÌ·½à  ËÕÖÝÊÐÁ¢Ò½Ôº

¼ò½é£ºÒ»Àý81ËêÄÐÐÔNSCLC»¼Õߣ¬2013Äê±»Õï¶ÏΪIBÆÚÏÙ°©(pT2aN0M0)¡£ÊÖÊõÖÎÁÆ3Äêºó¾±²¿¶à·¢Ö×´óÁܰͽᣬ»ùÒò¼ì²âÌáʾEGFRÍâÏÔ×Ó19ȱʧ¡£¸Ã»¼Õß½ÓÊÜÁË1¸öÁƳ̵ıê×¼¼ÁÁ¿ÅàÃÀÇúÈûÁªºÏ˳²¬ÖÎÁÆ£¬ÒòÁÆÐ§²»¼Ñ¸ÄΪ¼ª·ÇÌæÄá250mg/dÖÎÁÆ1¸öÔ£¬²¿·Ö»º½â£¬ºóÒò¸´·¢ÐÔµÏÍþ¹ú¼ÊÎïÏà¹ØÐÔ¸ÎËðÉ˸ÄÓð£¿ËÌæÄᣬµÚÒ»´úEGFR-TKIsÖÎÁÆ»º½â38¸öÔºóÆä²¡Çé½øÕ¹³öÏÖÁËT790MÍ»±ä¡£½ÓÊܰÂÏ£ÌæÄᣨ80mg/d£©ÖÎÁÆ£¬²¿·Ö»º½â£¬4¸öÔºó·¢Éú¼äÖÊÐÔ·ÎÑ×£¬Í£µÏÍþ¹ú¼Êºó»º½â£¬ÖØÐ¸øµÏÍþ¹ú¼Êºó¸´·¢£¬»»ÓÃ110mg/d°¢ÃÀÌæÄáÖÎÁÆ£¬ÁÆÐ§Îȶ¨£¬¼äÖÊÐÔ·ÎÑ×δ¸´·¢¡£


ÕªÒª±àºÅ£ºEP08.02-039

An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±ä·ÎÏÙ°©°éÓÐÖ¢×´µÄÄÔÄ¤×ªÒÆ

×÷ÕߣºÕÅÐÂÓ  Ê×¶¼Ò½¿Æ´óѧ¸½Êô±±¾©ÐØ¿ÆÒ½Ôº

¼ò½é£ºÒ»Àý53ËêÅ®ÐÔ»¼ÕßÕï¶ÏΪ×ó·ÎÏÙ°©°éÄÔĤ¡¢ÄÔ×ªÒÆ£¬EGFR 19del£¬³õÕïʱͷʹŻÍÂÖ¢×´Ã÷ÏÔ£¬Â­ÄÚѹ´óÓÚ320mm H?O£¬PSÆÀ·Ö4·Ö£¬Óð¢ÃÀÌæÄá220mg/dÖÎÁÆ3ÌìºóÖ¢×´Ã÷ÏÔºÃת£¬»¼Õß¿É×ÔÖ÷½øÊ³£¬¸ÄΪ³£¹æ¼ÁÁ¿110mg/d£¬12Ììºó­ÄÚѹ½µÖÁÕý³£Öµ£¬PSÆÀ·Ö1·Ö¡£¿¼ÂÇÖ×Áö¸ººÉÖØ£¬¿ªÊ¼ÁªºÏ±´·¥Öéµ¥¿¹Î¬³ÖÖÎÁÆ£¬PFS´ï15¸öÔ£¬°²È«ÐÔÁ¼ºÃ¡£


ÕªÒª±àºÅ£ºEP08.02-095

Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib

°¢ÃÀÌæÄáÖÎÁÆEGFR 19ȱʧ°éTP53ºÍERBB2 20²åÈëÍ»±äIVBÆÚNSCLC

×÷ÕߣºÁõ´ºÁá  Ð½®Ò½¿Æ´óѧ¸½ÊôÖ×ÁöÒ½Ôº

¼ò½é£ºÒ»Àý55Ë껼ÕßÕï¶ÏΪ¡°×ó·ÎÉÏÒ¶ÏÙ°©IVBÆÚ£¬Ë«²à·ÎÃÅ¡¢×ÝëõÁܰͽᡢ˫·Î¡¢¶à·¢¹Ç×ªÒÆ¡±£¬»ùÒò¼ì²â½á¹ûÌáʾΪEGFR 19DelºÏ²¢TP53Í»±ä¡£»¼Õß¾ßÓÐÂýÐÔÒÒÐ͸ÎÑײ¡Ê·20ÓàÄê¡£Ò»ÏßÖÎÁÆ·½°¸£º¿Ú·þ¼ª·ÇÌæÄᣬ×î¼ÑÁÆÐ§PR£¬PFS1=9¸öÔ¡£Ëæºó³öÏÖз¢×ªÒÆÔ¿¼ÂǼ²²¡½øÕ¹£¬ÔٴλùÒò¼ì²âÏÔʾERBB2 20ins²¢EGFR 19Del²¢TP53Í»±ä¡£¶þÏßÖÎÁÆ·½°¸£º»¼Õ߿ڷþ°¢ÃÀÌæÄá110mg£¬·Î²¿²¡Ôî×î¼ÑÁÆÐ§PR£¬PFS 2=7¸öÔ£¬ÄÍÊÜÐԽϺã¬Î´³öÏָι¦ÄÜËðÉË¡£ºóÒòÔ­·¢²¡Ôî½ÏǰÔö´ó£¬¾±²¿ºÍËø¹ÇÇø¶à·¢Áܰͽá×ªÒÆ¡£ÔÚÈýÏßÖÎÁÆ·½°¸¡ª¡ªÑ¡ÔñA£«T£«C·½°¸£¨¿Ú·þ°¢ÃÀÌæÄá110mg£¬Í¬Ê±ÁªºÏÅàÃÀÇúÈû6ÖÜÆÚºÍ±´·¥Öéµ¥¿¹¡£Ô­·¢²¡Ôî¼°×ªÒÆÔî¾ùËõС£¬Ñ×ÐÔÉø³öÎüÊÕ£¬ÕûÌåÁÆÐ§ÎªSD¡£ÈýÏßÖÎÁƺóµÄά³Ö·½°¸¡ª¡ª¼ÌÐø¿Ú·þ°¢ÃÀÌæÄá110mg£¬Í¬Ê±ÁªºÏ±´·¥Öéµ¥¿¹£¬Ä¿Ç°PFS 3>13¸öÔ£¬¸Ã»¼ÕßÈÔÔÚËæ·ÃÖС£×ܽ᣺¸Ã»¼ÕßĿǰÕûÌåPFS£¾29¸öÔ£¬Ê¹ÓÃÒÔ°¢ÃÀÌæÄáΪºËÐĵÄÖÎÁÆ·½°¸ÆÚ¼ä£¬PFS£¾20¸öÔ£¬¼²²¡¿ØÖÆÁ¼ºÃ¡£ÖÎÁƹý³ÌÖнö³öÏÖ1-2¼¶²»Á¼·´Ó¦£¬²¿·Ö²»Á¼·´Ó¦¿¼ÂÇÓëÁªºÏ»¯ÁƵÏÍþ¹ú¼ÊÎïÏà¹Ø£¬ÕûÌåÄÍÊÜÐÔÁ¼ºÃ¡£


ÕýÔÚ½øÐÐÖеÄÁÙ´²Ñо¿

ÕªÒª±àºÅ£ºEP08.02-001

Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

°¢ÃÀÌæÄáÁªºÏͬ²½·ÅÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆ

×÷ÕߣºÍõÓ±  ÖØÇì´óѧ¸½ÊôÖ×ÁöÒ½Ôº


ÕªÒª±àºÅ£ºEP05.02-009

Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)

°¢ÃÀÌæÄá¶Ô±È¶òÂåÌæÄá»ò»¯ÁÆÐ¸¨ÖúÖÎÁÆEGFRÍ»±äIIIAÆÚNSCLC£¨ANSWERÑо¿£©

×÷ÕߣºÁºÎÄ»ª  ¹ãÖÝÒ½¿Æ´óѧ¸½ÊôµÚÒ»Ò½Ôº


ÕªÒª±àºÅ£ºEP05.02-016

Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

Êõºó¸¨Öú·Å»¯ÁÆÐò¹á°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äpIIIA-N2ÆÚNSCLC

×÷ÕߣºÕÅ褠 ¹óÖÝÊ¡ÈËÃñÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-021

A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases

°¢ÃÀÌæÄáÁªºÏ·ÅÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆ

×÷ÕߣºÏıù  º¼ÖÝÊÐÖ×ÁöÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-051

High-dose Aumolertinib as First-line Treatment in Patients with Brain Metastases Associated with EGFR Mutated NSCLC

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆ

×÷Õߣº·¶ÔÆ  Õã½­Ê¡Ö×ÁöÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-057

Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance

°¢ÃÀÌæÄá¶þÏßÖÎÁÆÄ͵ÏÍþ¹ú¼ÊÆ×Ñо¿

×÷Õߣº·ëÁäöΠ Çൺ´óѧ¸½ÊôÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-067

Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

°¢ÃÀÌæÄáÁªºÏ°£¿ËÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLCÄÔ×ªÒÆ»¼Õß

×÷Õߣº»ÆÃÄ¾ê  ËÄ´¨´óѧ»ªÎ÷Ò½Ôº


ÕªÒª±àºÅ£ºEP08.02-077

Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes

°¢ÃÀÌæÄáÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äºÏ²¢·ÇEGFRÇý¶¯»ùÒòÍ»±ä/ÒÖ°©»ùÒòÍ»±äNSCLC£¨ACROSSÑо¿£©

×÷ÕߣºÍõ½à  Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-094

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä·ÎÏÙÁÛ°©£¨ARISEÑо¿£©

×÷ÕߣºÁÖ¸ù  ¸£½¨Ê¡Ö×ÁöÒ½Ôº


ÕªÒª±àºÅ£ºEP08.02-137

Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment

°¢ÃÀÌæÄáÖÎÁƾ­°ÂÏ£ÌæÄáÖÎÁƺó°²È«ÐÔ²»ÄÍÊܵÄEGFRÍ»±äÍíÆÚNSCLC£¨ACTIVEÑо¿£©

×÷ÕߣºÂ½Ë´  ÉϺ£ÊÐÐØ¿ÆÒ½Ôº


ÕªÒª±àºÅ£ºEP08.03-001

A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases

°¢ÃÀÌæÄáÁªºÏSBRTÖÎÁÆEGFRÍ»±äNSCLCÄÔʵÖʹÑ×ªÒÆ

×÷ÕߣººØ´ºÓï  ºÓÄÏÊ¡Ö×ÁöÒ½Ôº


Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬²é¿´°¢ÃÀÌæÄá±¾½ìWCLCÈëѡժҪµÄÏêϸÐÅÏ¢£º
https://library.iaslc.org/conference-program?product_id=25


´Ë´ÎÈëÑ¡µÄ21ƪ°¢ÃÀÌæÄáÕªÒª£¬½«ÓÚ»áÒéÕÙ¿ªÆÚ¼ä¹«²¼¸ü¶àÐÅÏ¢µÄPoster£¬¾´ÇëÆÚ´ý£¡

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿